This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Chinook Therapeutics Valuation

Is 290A undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

Below Fair Value
Significantly Below Fair Value
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 290A when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate 290A's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate 290A's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 290A?

Key metric: As 290A barely has revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for 290A. This is calculated by dividing 290A's market cap by their current book value.
What is 290A's PB Ratio?
PB Ratio	8.1x
Book	US$357.04m
Market Cap	US$2.90b

290A key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	450.5x
Enterprise Value/EBITDA	-11.6x
PEG Ratio	n/a

Price to Book Ratio vs Peers

How does 290A's PB Ratio compare to its peers?

The above table shows the PB ratio for 290A vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PB	Estimated Growth	Market Cap
Peer Average	2.1x
BIO3 Biotest	2x	29.3%	€1.3b
FYB Formycon	1.5x	31.5%	€857.2m
MOR MorphoSys	n/a	59.1%	€2.5b
HPHA Heidelberg Pharma	3x	-33.0%	€105.8m
290A Chinook Therapeutics	8.1x	22.6%	€2.9b

Price-To-Book vs Peers: 290A is expensive based on its Price-To-Book Ratio (8.1x) compared to the peer average (4.9x).

Price to Book Ratio vs Industry

How does 290A's PB Ratio compare vs other companies in the DE Biotechs Industry?

3 Companies	Price / Book	Estimated Growth	Market Cap
V9Z Aceragen	0.1x	n/a	US$3.12m
V9Z Aceragen	0.1x	n/a	US$2.18m
O7P NeuBase Therapeutics	0.1x	n/a	US$1.39m

No more companies available in this PB range

3 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Book vs Industry: 290A is expensive based on its Price-To-Book Ratio (8.1x) compared to the European Biotechs industry average (2.4x)

Price to Book Ratio vs Fair Ratio

What is 290A's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

290A PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio	8.1x
Fair PB Ratio	n/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate 290A's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 290A forecast and predictions for the stock price in 12 month’s time.
Date	Share Price	Average 1Y Price Target	Dispersion	High	Low	1Y Actual price	Analysts
Current	n/a	€36.58 0%	9.4%	€42.88	€27.37	n/a	11
Nov ’25	n/a	€36.58 0%	9.4%	€42.88	€27.37	n/a	11
Oct ’25	n/a	€36.58 0%	9.4%	€42.88	€27.37	n/a	11
Sep ’25	n/a	€36.58 0%	9.4%	€42.88	€27.37	n/a	11
Aug ’25	n/a	€36.58 0%	9.4%	€42.88	€27.37	n/a	11
Jul ’25	n/a	€36.58 0%	9.4%	€42.88	€27.37	n/a	11
Jun ’25	n/a	€36.58 0%	9.4%	€42.88	€27.37	n/a	11
May ’25	n/a	€36.58 0%	9.4%	€42.88	€27.37	n/a	11
Apr ’25	n/a	€36.58 0%	9.4%	€42.88	€27.37	n/a	11
Mar ’25	n/a	€36.58 0%	9.4%	€42.88	€27.37	n/a	11
Feb ’25	n/a	€36.58 0%	9.4%	€42.88	€27.37	n/a	11
Jan ’25	n/a	€36.58 0%	9.4%	€42.88	€27.37	n/a	11
Dec ’24	n/a	€36.58 0%	9.4%	€42.88	€27.37	n/a	11
Nov ’24	n/a	€36.58 0%	9.4%	€42.88	€27.37	n/a	11
Oct ’24	n/a	€36.58 0%	9.4%	€42.88	€27.37	n/a	11
Sep ’24	n/a	€36.58 0%	9.4%	€42.88	€27.37	n/a	11
Aug ’24	€35.40	€36.46 +3.0%	9.4%	€42.74	€27.28	n/a	11
Jul ’24	€35.00	€35.90 +2.6%	12.1%	€43.06	€27.49	n/a	11
Jun ’24	€22.40	€33.32 +48.7%	17.6%	€46.45	€27.32	n/a	12
May ’24	€18.00	€33.83 +87.9%	18.1%	€46.42	€27.30	n/a	12
Apr ’24	€21.00	€34.81 +65.8%	18.1%	€47.77	€28.10	n/a	12
Mar ’24	€21.20	€34.80 +64.2%	18.8%	€48.21	€28.36	n/a	11
Feb ’24	€22.80	€33.37 +46.3%	20.6%	€48.62	€26.69	n/a	9
Jan ’24	€24.00	€33.37 +39.0%	20.6%	€48.62	€26.69	n/a	9
Dec ’23	€21.00	€34.25 +63.1%	20.9%	€49.03	€26.92	n/a	8
Nov ’23	€22.00	€34.57 +57.2%	19.2%	€47.25	€27.56	n/a	8

Analyst Forecast: Target price is lower than the current share price.

Discover undervalued companies

Amneal Pharmaceuticals

US$2.6b

Develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide.

2DT

US$7.55

2.0%

95.6%

Collegium Pharmaceutical

US$993.0m

A specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management.

354

US$29.20

5.0%

23.7%

Pharming Group

€478.2m

A biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally.

PHGN

€0.72

1.8%

-31.2%